Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical study protocol no. VIA-2291-01, a phase 2 randomized, double-blind, parallel-group, placebo-controlled, dose-ranging study of the effect of VIA-2291 on vascular inflammation in patients after an acute coronary syndrome event

Next Previous
X
Search
Trial Profile

Clinical study protocol no. VIA-2291-01, a phase 2 randomized, double-blind, parallel-group, placebo-controlled, dose-ranging study of the effect of VIA-2291 on vascular inflammation in patients after an acute coronary syndrome event

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 10 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Atreleuton (Primary)
  • Indications Acute coronary syndromes
  • Focus Biomarker; Pharmacodynamics
  • Acronyms ACS
  • Sponsors Tallikut Pharmaceuticals

    • Most Recent Events

    • 12 Mar 2018 Results assessing the change in epicardial fat volume after treatment with atreleuton presented at the 67th Annual Scientific Session of the American College of Cardiology
    • 24 Nov 2016 Results (n=54) assessing the effect of atreleuton on coronary plague progression (serial CT angiography study) published in the Clinical Cardiology
    • 20 May 2010 Results have been published in in volume 3, issue 3 of the American Heart Association journal Circulation: Cardiovascular Imaging, published May 19, 2010, according to a VIA Pharmaceuticals media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top